Physician profile
Dhara Patel
NPI 1982284618
$285.88
in general payments reported to CMS, 2019-2025
12 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $85.32 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $285.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $39.02 | 2025 | Vevye |
| Boston Scientific Corporation | $33.75 | 2025 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $33.39 | 2024-2025 | |
| Esperion Therapeutics, INC. | $23.87 | 2024 | Nexletol |
| Phadia US INC. | $22.82 | 2025 | Immunocap |
| Merz North America, INC. | $21.39 | 2024 | |
| Novo Nordisk INC | $20.68 | 2025 | |
| Abbott Laboratories | $20.34 | 2024 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.44 | 2025 | Caplyta |
| Echosens North America, INC. | $18.80 | 2025 | Fibroscan |
| Fidia Pharma USA INC. | $17.57 | 2025 | Triluron, Hymovis |
| Lilly USA, LLC | $14.81 | 2025 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhara Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.